Published on : Jul 28, 2015
The immunological treatment of cancer has successfully attract the interests of leading medical institutions in China, despite concerns in other countries regarding the safety and effectiveness of the procedure.
According to latest reports, there are possibly eight listed companies in China that have entered the market segments associated with the immune cell treatment in the last two years. Companies such as Shanghai Yaoji Playing Card Company and Shanghai Canature Environmental Products Company have started allowing immune cell treatment in May, however it is only limited to clinical research purposes and not available for medical treatments.
Earlier in December 2014, Novartis, the prominent Swiss pharmaceutical company announced that its CAR-T immunological therapy holds promise for patients of blood cancer. The healthcare establishment is believed to have discovered the effectiveness of using the therapeutics for treating blood cancer. The medical establishment is already focusing its research activities to explore the effectiveness of using immune cells to treat lung and liver cancers.
An anonymous source revealed to China Business News in Shanghai, that blood cancer treatment using immune cells in the private medical institutions of United States costs anywhere between US$300,000 and US$400,000.
In the last few years, patients in China have discovered ways to obtain the treatment, since experts in the industry have suggested that the procedure has proven to be 80% effective against malignant tumors and can double the survival rates.
One session of immune cell treatment in China costs between US$1,600 and US$1,900 (10,000 yuan and 12,000 yuan). Likewise, the entire course is likely to cost between US$48,000 to US$80,000 depending on the number of rounds administered. However, it is important to note here in this regard that although the research perspective of immune cell treatment has been appreciated it is yet to get approval as a medical treatment.